Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 1

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

Authors Imad Sheiban, Gianluca Villata, Mario Bollati, Dario Sillano, Marzia Lotrionte, Giuseppe Biondi-Zoccai

Published 8 February 2008 Volume 2008:4(1) Pages 31—38

DOI https://dx.doi.org/10.2147/VHRM.S1838

Imad Sheiban1, Gianluca Villata1, Mario Bollati1, Dario Sillano1, Marzia Lotrionte2, Giuseppe Biondi-Zoccai1

1Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy; 2Institute of Cardiology, Catholic University, Rome, Italy

Abstract: Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher®) and paclitaxel-eluting stents (Taxus®), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. There are well known caveats on the performance of their respective metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation DES, such as zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®), have recently become available in the USA and/or Europe. The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. In addition, this stent is based on the Multi-link platform and delivery system. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without significant untoward events. Nonetheless, the number of patients studied and the follow-up duration are still too limited to enable definitive conclusions. Only indirect meta-analyses can be used to date to compare the Xience V with the Cypher. This systematic review tries to provide a concise and critical appraisal of the data in support of the Xience V everolimus-eluting stent.

Keywords: coronary artery disease, everolimus, percutaneous transluminal coronary angioplasty, stent

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Association between EHBP1 rs721048(A>G) polymorphism and prostate cancer susceptibility: a meta-analysis of 17 studies involving 150,678 subjects

Ao X, Liu Y, Bai XY, Qu X, Xu Z, Hu G, Chen M, Wu H

OncoTargets and Therapy 2015, 8:1671-1680

Published Date: 7 July 2015

Effects of exercise timing on sleep architecture and nocturnal blood pressure in prehypertensives

Fairbrother K, Cartner B, Alley JR, Curry CD, Dickinson DL, Morris DM, Collier SR

Vascular Health and Risk Management 2014, 10:691-698

Published Date: 12 December 2014

Stress echocardiogaphy: A useful test for assessing cardiac risk in diabetes

Rajan Sharma, Denis Pellerin

Vascular Health and Risk Management 2009, 5:1-7

Published Date: 24 November 2008

Prevalence and component analysis of metabolic syndrome: An Indian atherosclerosis research study perspective

Saikat Kanjilal, Jayashree Shanker, Veena S Rao, Natesha B Khadrinarasimhaih, Manjari Mukherjee, et al

Vascular Health and Risk Management 2008, 4:189-197

Published Date: 8 February 2008

A hazardous finding of a rare anomalous left main coronary artery in a patient with a secundum atrial septal defect

Michael Emery, Waqas Ghumman, Shawn Teague, Jo Mahenthiran

Vascular Health and Risk Management 2008, 4:259-262

Published Date: 8 February 2008

Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!

Claudia S Vetter-Kauczok, Philipp Ströbel, Eva B Bröcker, Jürgen C Becker

Vascular Health and Risk Management 2008, 4:263-266

Published Date: 8 February 2008

Carvedilol in hypertension treatment

Panagiotis C Stafylas, Pantelis A Sarafidis

Vascular Health and Risk Management 2008, 4:23-30

Published Date: 8 February 2008

Lipid-lowering effects of methanolic extract of Vernonia amygdalina leaves in rats fed on high cholesterol diet

Oluwatosin A Adaramoye, Olajumoke Akintayo, Jonah Achem, Michael A Fafunso

Vascular Health and Risk Management 2008, 4:235-241

Published Date: 8 February 2008

Current role of endovascular therapy in Marfan patients with previous aortic surgery

Ibrahim Akin, Stephan Kische, Tim C Rehders, Tushar Chatterjee, Henrik Schneider, et al

Vascular Health and Risk Management 2008, 4:59-66

Published Date: 8 February 2008

Adherence treatment factors in hypertensive African American women

Marie N Fongwa, Lorraines S Evangelista, Ron D Hays, David S Martins, David Elashoff, et al

Vascular Health and Risk Management 2008, 4:157-166

Published Date: 8 February 2008